Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by J.M. Rossi
Outcomes of Patients ≥ 65 Years of Age in Zuma-1, a Pivotal Phase 1/2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Refractory Large B Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Product Characteristics Associated With in Vivo Expansion of Anti-Cd19 Car T Cells in Patients Treated With Axicabtagene Ciloleucel (Axi-Cel)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Related publications
Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients With Refractory Aggressive Non-Hodgkin Lymphoma (NHL): Long-Term Follow-Up of the Pivotal Zuma-1 Trial
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Preliminary Results of Earlier Steroid Use With Axicabtagene Ciloleucel (Axi-Cel) in Patients With Relapsed/Refractory Large B Cell Lymphoma
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma
Clinical Cancer Research
Cancer Research
Oncology
Safety and Efficacy of Axicabtagene Ciloleucel (Axi-Cel) in Older Patients: Results From the Us Lymphoma Car-T Consortium
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Safety and Efficacy of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphomas
Therapeutic Advances in Hematology
Hematology
Axicabtagene Ciloleucel for CD19+ Plasmablastic Lymphoma
American Journal of Hematology
Hematology
A Phase 1/2 Study of Brentuximab Vedotin in Pediatric Patients With Relapsed/Refractory (R/R) Systemic Anaplastic Large-Cell Lymphoma (Salcl) or R/R Hodgkin Lymphoma (Hl)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Phase 2 Study of Parsaclisib (Incb050465) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (Dlbcl) (Citadel-202)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
